This agreement provides Sirtris with exclusive rights to intellectual property covered under the patent ‘cholesterol-regulating complex of SIRT1 and LXR and methods of use.’
Karl Normington, Sirtris’ senior director of intellectual property, said: “Sirtuins are attractive drug targets which may be therapeutically beneficial for metabolic, neurological, and cardiovascular diseases. This license further strengthens Sirtris’ intellectual property estate for drugs that may address diseases of aging.”